EMA's CHMP Recommends Approval for MSD's Keytruda Combo in Mesothelioma Treatment
CompanyDrug

EMA’s CHMP Recommends Approval for MSD’s Keytruda Combo in Mesothelioma Treatment

EMA's CHMP Recommends Approval for BMS's Opdivo/Yervoy Combo in mCRC
CompanyDrug

EMA’s CHMP Recommends Approval for BMS’s Opdivo/Yervoy Combo in mCRC

Boston Scientific Expands Neuromodulation Portfolio with Axonics Acquisition
CompanyDeals

Boston Scientific Expands Neuromodulation Portfolio with Axonics Acquisition

Sandoz Receives EC Approval for Biosimilar to Eylea for Retinal Diseases
CompanyDrug

Sandoz Receives EC Approval for Biosimilar to Eylea for Retinal Diseases

Peijia Medical Achieves First Compassionate Use of Taurus Trio TAVR System in Hong Kong
CompanyMedical Device

Peijia Medical Achieves First Compassionate Use of Taurus Trio TAVR System in Hong Kong

Sanofi's Dupixent sBLA for Chronic Spontaneous Urticaria Accepted by FDA for Review
CompanyDrug

Sanofi’s Dupixent sBLA for Chronic Spontaneous Urticaria Accepted by FDA for Review

Novo Nordisk Launches Semaglutide for Weight Management in China
CompanyDrug

Novo Nordisk Launches Semaglutide for Weight Management in China

Sichuan Kelun-Biotech Secures NMPA Approval for Two Antibody Drug Conjugates
CompanyDrug

Sichuan Kelun-Biotech Secures NMPA Approval for Two Antibody Drug Conjugates

Exegenesis Bio's Gene Therapy EXG110 Earns FDA Orphan Drug Designation for Fabry Disease
CompanyDrug

Exegenesis Bio’s Gene Therapy EXG110 Earns Orphan Drug Status for Fabry Disease

Shenzhen Weiguang Biological Partners with SUAT to Boost Life Science and Health Industry
CompanyDeals

Shenzhen Weiguang Biological Partners with SUAT to Boost Life Science and Health Industry

Janssen-Cilag's Lazcluze-Rybrevant Combo Receives Positive EMA Opinion for NSCLC Treatment
CompanyDrug

Janssen-Cilag’s Lazcluze-Rybrevant Combo Receives Positive EMA Opinion for NSCLC Treatment

Shanghai Junshi Biosciences' Toripalimab Wins UK Approval for Nasopharyngeal and Oesophageal Cancers
CompanyDrug

Shanghai Junshi Biosciences’ Toripalimab Wins UK Approval for Nasopharyngeal and Oesophageal Cancers